SCHEMBL425856

SCHEMBL425856

CC1(C)COCN1C(=O)n1cnc(-c2ccc(Cl)cc2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.39
BCHE P06276 2/20 0.36
LIPE Q05469 2/20 0.36
XPO1 O14980 1/20 0.35
KMT2A Q03164 4/20 0.34
MEN1 O00255 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
DPP4 P27487 1/20 0.34
DPP8 Q6V1X1 1/20 0.34
DPP9 Q86TI2 1/20 0.34
GRM5 P41594 2/20 0.33
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
ACHE P22303 1/20 0.33
RAB9A P51151 2/20 0.33
GAA P10253 1/20 0.33
KLK7 P49862 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
KLK14 Q9P0G3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL427872 0.88 ALDH1A1 (0.36) CNR2KMT2AKDM4EALDH1A1HPGD
SCHEMBL424515 0.82 PARP10 (0.38) CNR2XPO1KMT2AMEN1KDM4E
SCHEMBL427034 0.77 HDAC1 (0.38) CNR2KMT2AL3MBTL1KDM4EALDH1A1
SCHEMBL427118 0.77 DPP4 (0.40) CNR2DPP4DPP8DPP9GRM5
SCHEMBL424504 0.76 CNR2 (0.39) CNR2DPP4GRM5
SCHEMBL427139 0.75 CNR2 (0.37) CNR2KMT2AMEN1L3MBTL1DPP4
SCHEMBL425576 0.74 LIPE (0.56) BCHELIPEKMT2AMEN1L3MBTL1
SCHEMBL425699 0.73 PARP10 (0.41) KMT2AALDH1A1
SCHEMBL425673 0.70 POLB (0.51) BCHELIPEKDM4EALDH1A1HPGD
SCHEMBL425860 0.68 ALDH1A1 (0.46) BCHELIPEXPO1DPP4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 CNR2 9/4885BCHE 93/4885LIPE 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.